{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:17:13Z","timestamp":1787563033716,"version":"build-2736575974"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105760","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T21:38:42Z","timestamp":1720129122000},"page":"105760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Underdosed generic specialty medications: A prescription for patient harm?"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-1523","authenticated-orcid":false,"given":"Darin T.","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatum M.","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahi A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2024.105760_bib0001","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lanc. Neurol."},{"key":"10.1016\/j.msard.2024.105760_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105393","article-title":"Author's addendum to the article: fingolimod: assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteria","volume":"82","author":"Greenwood","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105760_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad073","article-title":"The radiologically isolated syndrome: revised diagnostic criteria","author":"Lebrun-Frenay","year":"2023","journal-title":"Brain"},{"issue":"14","key":"10.1016\/j.msard.2024.105760_bib0004","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105760_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103920","article-title":"Hiding in plain sight: the magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care","volume":"63","author":"Okuda","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105760_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105077","article-title":"Fingolimod: assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteria","volume":"80","author":"Wainwright","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T23:22:22Z","timestamp":1723591342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":6,"alternative-id":["S2211034824003377"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105760","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underdosed generic specialty medications: A prescription for patient harm?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105760"}}